Comparing Clipping of the Heart's Left Atrial Appendage With Blood Thinners in Atrial Fibrillation
Tests a heart clipping procedure against blood-thinning pills in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: LAA Clipping Versus NOACs to Prevent Stroke in Non-paroxysmal Atrial Fibrillation.
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with persistent or long-standing persistent atrial fibrillation who are at high risk of stroke and agree to a keyhole (thoracoscopic) procedure to close the left atrial appendage.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Persistent or long-standing persistent atrial fibrillation, shown by medical history or an ECG. CHA2DS2-VASc score of at least 2 in men and at least 3 in women.
- Earlier treatment
- Not planning electrical cardioversion or ablation. No previous heart or left lung surgery.
Main reasons for not taking part
- Planned electrical cardioversion or ablation
- Stroke or other heart-related embolic event, or major bleeding, in the last 30 days
- Cannot take blood thinners (anticoagulants)
- Left ventricular ejection fraction below 30%
- Pregnant or breastfeeding
Read by machine on 9 November 2026.
Where in China
- China National Center for Cardiovascular DiseasesBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China National Center for Cardiovascular Diseases
- Trial code
- NCT06021808
- Record updated
- 13 June 2024
- Original description
This trial is designed to examine the hypothesis that thoracoscopic LAA clipping is superior to NOACs for stroke, systemic embolism, all-cause mortality, major bleeding events and clinically relevant nonmajor bleeding events in AF patients at high risk of embolism (CHA2DS2-VASc ≥2 in men and ≥3 in women) that are not undergoing ablation.Read full original descriptionShow less
Epicardial Left Atrial Appendage Clipping Versus Novel Oral Anticoagulants to Reduce Stroke Risk in Non-paroxysmal Atrial Fibrillation: a Multicenter Randomized Controlled Trial
This trial is designed to examine the hypothesis that thoracoscopic LAA clipping is superior to NOACs for stroke, systemic embolism, all-cause mortality, major bleeding events and clinically relevant nonmajor bleeding events in AF patients at high risk of embolism (CHA2DS2-VASc ≥2 in men and ≥3 in women) that are not undergoing ablation.
Inclusion: Age ≥ 18 years; Persistent or long-standing persistent AF documented by medical history or direct electrocardiogram; CHA2DS2-VASc ≥2 in men and ≥3 in women; Agree to perform thoracoscopic LAA occlusion procedure.
Exclusion: Patients requiring dual antiplatelet drug therapy; Previous cardiac and left lung surgery; Other heart diseases with surgical indications; Ischemic stroke and other cardiac embolic events within 30 days; Major clinical bleeding event within 30 days; Active systemic infection or infective endocarditis or pericarditis; Other diseases requiring oral anticoagulants; Acute coronary syndrome within 3 months; Metal allergies; Terminal illness with a life expectancy of less than 2 years; Left ventricular ejection fraction (LVEF) < 30%; Severe liver disease (acute clinical hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT)/ aspartate transaminase (AST) greater than 3 times the upper limit of normal value; Severe renal insufficiency (eGFR ≤ 30mL/min); With electrical cardioversion or ablation intent; Contraindications to anticoagulation; Intracardiac thrombus; Active aortic plaque; Symptomatic carotid artery stenosis; Severe left pleural and pericardial adhesions; Pregnant or breastfeeding patients; Participation in other clinical studies at the time of enrollment; Refuse to participate in this study.